In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems (UG3/UH3 Clinical Trials Not Allowed
ID: 357477Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems" under the cooperative agreement mechanism (UG3/UH3), aimed at advancing optical imaging technologies to address the challenges of light scattering in biological tissues. This initiative seeks to develop next-generation non-invasive or minimally-invasive optical imaging techniques that enhance penetration depth and resolution, thereby improving diagnostic and research capabilities in biomedical fields. With a total funding commitment of approximately $4.9 million available over a maximum project period of three years, eligible applicants include higher education institutions, non-profits, and small businesses, all of which must submit their proposals electronically through Grants.gov by February 7, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    Files
    Title
    Posted
    The National Institutes of Health (NIH) is issuing a Notice of Funding Opportunity (NOFO) focused on advancing In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems, with a funding opportunity number RFA-RM-24-012. This initiative aims to overcome the challenges posed by light scattering in biological tissues, which limits the depth and resolution of current optical imaging techniques. The NIH is encouraging the development of next-generation optical imaging technologies capable of providing high-resolution images across various biological scales, enhancing both diagnostic and research applications. Funding is available through a phased cooperative agreement mechanism (UG3/UH3), allowing for a maximum project period of three years, with initial support of two years followed by a potential one-year extension based on progress. Eligible applicants include higher education institutions, non-profits, and small businesses, with a total funding commitment of approximately $4.9 million anticipated. A key requirement for applicants is the Plan for Enhancing Diverse Perspectives (PEDP) to encourage inclusivity in research teams. Submissions must be made electronically through Grants.gov by February 7, 2025, encapsulating plans for innovative optical imaging technologies that can significantly improve penetration depth and resolution while addressing crucial biomedical challenges.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for In Vivo Non-Invasive Optical Approaches for Biological systems (UG3/HU3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is planning to publish a Notice of Funding Opportunity (NOFO) for the "Advancing Non-Invasive Optical Approaches for Biological Systems" initiative, aimed at developing next-generation optical imaging techniques. This initiative seeks to address the challenges of light scattering in biological systems, enabling high-resolution imaging at greater depths within tissues, and will support three-year bi-phasic research projects through UG3/UH3 Cooperative Agreements. With an estimated total program funding of $4.9 million and an award ceiling of $1.6 million, the NIH anticipates issuing the NOFO in December 2024, with applications due by March 2025 and awards expected to be made by December 2025. Interested applicants are encouraged to prepare collaborative proposals in advance of the official announcement.
    Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems," aimed at fostering collaborations between academic institutions and industrial organizations to enhance imaging technologies for cancer diagnosis and treatment. This initiative seeks to translate scientific discoveries and engineering advancements into practical tools that address significant challenges in cancer research, focusing on the development and validation of imaging systems that improve detection and treatment monitoring. The grant offers a maximum budget of $500,000 per year for up to five years, with applications required to include at least one academic and one industrial investigator. Interested applicants can find more information and submit their proposals by the deadline of January 7, 2027, by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-259.html.
    Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems," aimed at fostering collaborations between academic and industrial entities to enhance imaging technologies for cancer-related challenges. This initiative encourages innovative proposals that detail mechanisms for clinical relevance and operational feasibility, with a focus on advancing the development and validation of imaging systems that can improve cancer detection, diagnosis, and treatment. Funding is available for projects with budgets capped at $500,000 per year for up to five years, and applications must involve at least one academic and one industrial investigator. Interested applicants should submit their proposals electronically by January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "National Centers for Biomedical Imaging and Bioengineering (NCBIB)" aimed at supporting the development and dissemination of new biomedical technologies. This initiative encourages applications from a diverse range of eligible entities, including higher education institutions and nonprofit organizations, to conduct technology research and development projects, collaborative projects, and service projects that address biomedical challenges. The program is designed to foster innovative research and enhance clinical applications, with funding typically ranging from $600,000 to $750,000 per project, and awards may last up to five years, with a total funding cap of fifteen years for any Center. Interested applicants should note that the application process opens on September 25, 2023, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-23-235.html.
    Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through a cooperative agreement aimed at advancing in vivo high-resolution imaging technologies for inner ear visualization, specifically under the announcement RFA-DC-24-005. This initiative seeks to support high-risk clinical trials that enhance existing imaging techniques or develop new technologies capable of visualizing inner ear structures with significantly greater detail and accuracy in awake patients. The program emphasizes the importance of multidisciplinary collaboration and is particularly focused on projects that may require FDA oversight or involve higher participant risks, with a total funding amount of $2 million available for 2-4 awards, each with a maximum budget of $500,000 per year for up to five years. Interested applicants must submit their proposals by January 1, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "In Vivo High-Resolution Imaging for Inner Ear Visualization," aimed at advancing imaging technologies for the non-invasive visualization of the inner ear in living patients. This initiative seeks to support the development of both new and improved imaging techniques that can provide detailed insights into inner ear structures, such as hair cells and membranes, with a focus on applications that can be utilized in awake patients. The program is particularly significant for enhancing the diagnosis and treatment of inner ear disorders, reflecting NIH's commitment to innovative health research. A total of $2 million is allocated for 2-4 awards in fiscal year 2024, with applications opening on January 1, 2024, and a closing date for submissions set for June 3, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Notice of Funding Opportunity for National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a Notice of Funding Opportunity (NOFO) for the National Centers for Biomedical Imaging and Bioengineering (NCBIB), with a focus on advancing research in biomedical imaging and bioengineering. This grant opportunity, identified as P41 Clinical Trials Optional, aims to foster meaningful collaborations and innovative projects within the research community. The anticipated funding amount for this initiative is up to $750,000, with the NOFO expected to be published in late summer 2023 and applications due in fall 2023. Interested applicants should prepare for the estimated project start date of July 30, 2024, and can expect the award announcement by June 30, 2024.
    Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research between academic institutions and industrial partners to accelerate the development of innovative bioengineering tools addressing critical biomedical challenges. This initiative seeks multidisciplinary teams that integrate engineering principles to create robust solutions capable of enhancing life sciences understanding and medical practices within a 5-10 year timeframe. The program emphasizes the importance of partnerships in overcoming development barriers and facilitating technology validation and commercialization, ultimately aiming to improve patient health outcomes. Interested applicants can find more details and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by January 7, 2025.
    NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) aimed at accelerating the translation of innovative laboratory research into therapeutic interventions for visual system diseases. This program employs a bi-phasic, milestone-driven mechanism consisting of an Exploratory (R61) phase lasting up to two years and a Developmental (R33) phase lasting up to three years, focusing on generating preclinical data that supports applications for Investigational New Drug (IND) or Investigational Device Exemption (IDE) submissions to the FDA. The initiative is designed to engage diverse organizations, including historically black colleges, tribal governments, and community-based organizations, to foster collaborative efforts in ocular research, ultimately improving health outcomes through vision research. Interested applicants can find more information and guidelines at the provided link, with a funding ceiling of $500,000 and a submission deadline of March 16, 2025.
    Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research partnerships between academic and industrial investigators to accelerate the development of innovative bioengineering tools and technologies. The program seeks to establish multidisciplinary teams that apply a quantitative bioengineering approach to address significant biomedical challenges, with a focus on creating robust solutions that can enhance life science understanding and medical practices within a 5-10 year timeframe. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and for-profit entities, particularly those emphasizing diversity in research. Interested parties should note that the application deadline is September 7, 2027, and for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAR-24-325.html.